NCT04354675 is a NA clinical trial of Automated program (ChatBot) in Breast Cancer, sponsored by Case Comprehensive Cancer Center.

Who is sponsoring NCT04354675?

NCT04354675 is sponsored by Case Comprehensive Cancer Center.

What drugs are being tested in NCT04354675?

Interventions in NCT04354675: Automated program (ChatBot), Genetics counselor, BCGCKQ Survey, Satisfaction Survey, Genetic testing.

What condition does NCT04354675 study?

NCT04354675 studies Breast Cancer.

Is NCT04354675 still recruiting?

NCT04354675 is currently completed. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT04354675

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer

Completed NA Last updated 31 March 2026

What this trial tests

NA trial testing Automated program (ChatBot) in Breast Cancer in 35 participants. Completed in 30 March 2023.

Timeline

29 June 2021

Primary endpoint
30 March 2023

30 March 2023

Quick facts

Lead sponsor	Case Comprehensive Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	35
Start date	29 June 2021
Primary completion	30 March 2023
Estimated completion	30 March 2023
Sites	1 location across United States

Drugs / interventions tested

Automated program (ChatBot)
Genetics counselor
BCGCKQ Survey
Satisfaction Survey
Genetic testing

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Case Comprehensive Cancer Center — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to help better understand the uptake and impact of genetic testing for women diagnosed with breast cancer who do not meet National Comprehensive Cancer Network (NCCN) criteria for genetic testing. By doing so, the research team will gain a better understanding of the clinical implications for offering genetic testing for all patients recently diagnosed with breast cancer versus only offering genetic testing to those meeting NCCN criteria. By offering genetic counseling and genetic testing to all women recently diagnosed with breast cancer, there will be a shortage of genetic counselors. This study will also assess the feasibility of using artificial intelligence to assist in the genetic counseling process.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions.
Lotter W, Hassett MJ, Schultz N, Kehl KL, et al · · 2024 · cited 91× · PMID 38597966 · DOI 10.1158/2159-8290.cd-23-1199
Chatbot Artificial Intelligence for Genetic Cancer Risk Assessment and Counseling: A Systematic Review and Meta-Analysis.
Webster EM, Ahsan MD, Perez L, Levi SR, et al · · 2023 · cited 24× · PMID 37934933 · DOI 10.1200/cci.23.00123
Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches.
Xulu KR, Nweke EE, Augustine TN. · · 2023 · cited 7× · PMID 37662839 · DOI 10.3389/fgene.2023.1087432

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Case Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06811454 — Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) · NA · not yet recruiting
NCT07167056 — Artificial Intelligence-Powered Support For Quality Of Life Improvement In Participants With Cancer · NA · recruiting
NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
NCT07044362 — Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04354675 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Case Comprehensive Cancer Center
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04354675.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing